Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Stock Information for Lantern Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lantern Pharma Inc.

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Lantern Pharma Secures USPTO Notice of Allowance for LP?284 Treatment Patent in Aggressive B?Cell Lymphomas
Lantern Pharma to Present Open-Medicine AI - a Multi-Agentic Platform for End-to-End Therapeutic Development - Business Model, Roadmap, and Value Proposition on September 23
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.